Solvent resistant microfluidic DNA synthesizer.
Order of magnitude cost reduction without array synthesis
By forming alliances with Dentsu Group clients and partner companies, Dentsu Ventures will support Twist Bioscience's innovative business development.
Profiles of Twist Bioscience and Dentsu Ventures are provided below.
Profile of Twist Bioscience
Company Name: Twist Bioscience Corporation
Location: San Francisco, California, U.S.A.
Representative: Emily LeProust (CEO)
Line of Business: Providing High-Throughput DNA Synthesis for Multiple Industries
Profile of Dentsu Ventures
Name: Dentsu Ventures Global Fund I
Total Fund Capital: 10.0 billion yen
Date of Establishment: April 2015
Period of Operation: Slated for 10-year period, through March 2025
Investment Regions: Global investments with a focus on the U.S., Europe Japan and Asia
Investment Stages: Balanced, wide-ranging investments with the focus on seed and early stage investments, but also including mid-stage and later-stage investments
(1) Areas that can change the marketing and communication business in a broad sense
(2) New areas other than the above that have a high potential for innovation
DNA synthesis companies: cost per base, turn-around …
The second important thing to notice about these plots is that I have changed the name of the metric from “cost” to “price”. Previously, I had decided that this distinction amounted to no real difference for my purposes. Now, however, the world has changed, and cost and price are very different concepts for anyone thinking about the future of DNA. Previously, there was at times an order of magnitude change in cost from year to year, and keeping track of the difference between cost and price didn’t matter. In a period when change is much slower, that difference becomes much more important. Moreover, as the industry becomes larger, more established, and generally more important for the economy, we should all take more care in distinguishing between concepts like cost and price .